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Abstract
Opioid dependence plagues the United States with millions of
people suffering from the effects. Throughout recent years,
there has been a surge in research in treatment options for
patients suffering from opioid dependence. Three medications
have stood out: methadone, buprenorphine, and naltrexone. The
purpose of this study was to investigate the three and decipher
which provides the best outcomes for patients. Research was
conducted by reviewing literature via PubMed, PsychInfo and
Cochrane. A review of the literature found that methadone has
been used the longest and has been shown to be efficacious, but
can be severely limiting for patients due to lack of clinics and
the need for daily dosings. As a result, buprenorphine was
developed as an alternative medication with similar efficacy and
retention rates to combat the daily dosages and provide a more
readily available medication. Unfortunately buprenorphine also
has geographical limitations. Naltrexone is the newest
medication added to the mix. Orally, it has poor retention, but
an extended release form has been developed that is showing
promise. There are no geographical limitations associated with
naltrexone and the extended release form allows for only
monthly injections. Going forward with opioid treatment,
medications like naltrexone and those that are more readily
available will become more widely used for treatment as patient
preference is pointing towards medications that are not limited
by geography or frequent dosing.

Introduction
•Opioid addiction plagues our country. Short term opioid use has
been shown to be beneficial for patients, but many of those
patients continue to receive opioids for years (Lembke,
Humphreys, & Newmark, 2016). The addiction ranges from
patients receiving chronic opioid prescriptions to those buying
them on the street and abusing. This epidemic has become a
significant public health problem. There is increased morbidity
and mortality associated with opioid use, as well as an increase in
the spread of HIV and hepatitis (Nielsen et al., 2016).
•Opioid maintenance therapy has been shown to reduce the use of
abused opioids. Patients are able to return to normal social
functioning and decrease their criminal activity. This also
decreases the transmission of infectious diseases such as HIV and
hepatitis (Nunes et al.,2015).
•The Substance Abuse and Mental Health Services Administration
endorses three medications to use for opioid maintenance
treatment: buprenorphine, methadone, and naltrexone. While all
three have their benefits and their challenges, this researcher has
reviewed the current literature to make an informed decision as to
which is the best treatment option of the three (buprenorphine,
methadone, and naltrexone) for patients in need of opioid
maintenance treatment.

Statement of the Problem
• With the increasing opioid addiction epidemic in our country,
effective treatment options are necessary to reverse the trend.
Many different pharmacological options are available for opioid
maintenance therapy, but research is needed to show which
medication has the best efficacy taking into factor such aspects as
relapse rates and patient compliance.

Research Question
• Of the three pharmacological opioid maintenance therapy
options endorsed by the Substance Abuse and Mental Health
Services administration: methadone, buprenorphine, and
naltrexone, which has the best outcomes for patients taking into
account efficacy, retention rate, availability, and patient
preference?

Literature Review
A review of the literature provided the following main points:
- Methadone
- Schukit (2016) states that methadone is superior to placebo
for both managing withdrawal and retention in treatment
plans.
- Per Uebelaker et al. (2015), patients do not feel that
methadone is the best treatment option, noting barriers such
as location and time. They do not feel they are drug free.
- Buprenorphine
- Nielsen et al. (2016) found that buprenorphine and
methadone have similar retention and efficacy, but that
buprenorphine may be safer as it has less sedation and
respiratory depression.
- Lobmaier et al. (2010) discussed the abuse potential of
buprenorphine and as such recommend the combination of
buprenorphine and naloxone.
- Rosenthal (2013) researched an implantable form of
buprenorphine that was found to be three times as effective
as placebo and similar to sublingual buprenorphine.
- Naltrexone
- Lobmaier et al. (2010) found that oral naltrexone is similar
only to placebo except in highly motivated individuals for
treatment.
- Nunes et al. (2015) researched an extended release form
that has significantly better outcomes than placebo and
oral. At 24 weeks, 80% of patients had drug free urines as
compared to 15% of patient on oral.
- Dakwar and Kleber (2015) proposed that the injectable
naltrexone can be used to discontinue buprenorphine. For
the six patients in the study, only one injection was needed
to discontinue use.

Discussion
Methadone has been used the longest for opioid maintenance
treatment. It is tried and true, but patient preference is poor.
Patients are limited by location of methadone clinics and the
daily dosages.
Buprenorphine is a newer medication, but has shown similar
retention and efficacy to methadone. Providers are still limited
by certification, but not location so are more abundant. Dosage
is not daily.
Naltrexone is the newest treatment of the three. It is little better
than placebo as an oral medication, but has shown promise in
extended release and implantable forms. These forms allow for
at least a month of treatment per dose and have also been used
to discontinue the use of buprenorphine. There is also no
limitations to prescribers.
Naltrexone allows for more patient autonomy and reduces the time
and travel barriers seen with buprenorphine and methadone. It
can bring opioid treatment to rural areas that otherwise were
without.
Medications for Rehabilitation from an Opioid-Use Disorder,
According to the Patient’s Treatment Goal.
Stage or
Function

Action

Restriction

Full
Abstinence
from Opioids
Naltrexone
Blocks opioid
high

Opioid Maintenance

Methadone
Long-term
maintenance with the
use of an oral,
long-acting opioid

Patient must No misuse of
be opioid-free depressant drugs or
medical
contraindications;
can be used only in
specialized programs,
not in office-based
practices

Buprenorphine
Long-term
maintenance with
the use of an oral,
long-acting opioid

No misuse of
depressant drugs or
medical
contraindications;
can be used in
offices of
physicians
with special
training

Schukit, M. A., M.D. (2016, July 2). Treatment of Opioid-Use Disorders. The New England Journal of Medicine, 375(4), 357-368. Retrieved
September 26, 2016, from Pubmed.

Applicability to Clinical Practice
First and foremost, there must be a change in how opioids are
prescribed by providers. CDC came out with revised guidelines
in March of 2016 for primary care providers addressing when to
prescribe, how to select, and how to assess and address risk with
patients.
Treatment options must also change. Patient preference affects
treatment and preference has been towards long acting

medications that require little travel and little time
constraints. Drugs like methadone need to be more
readily available and have more effective delivery
methods.
A third shift must be in attitudes towards opioid misuse. It
is a chronic disease similar to hypertension and
diabetes. Patients and providers alike must realize
that like any other chronic disease, treatment may be
on going.
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